Alzamend Neuro (ALZN) Long-Term Debt Issuances (2020)
Alzamend Neuro's (ALZN) quarterly Long-Term Debt Issuances came in at $62110.0 in Q3 2020.
Powered by 
Analysis
Alzamend Neuro (ALZN) Long-Term Debt Issuances (2020) Analysis & Trends
Alzamend Neuro has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $62110.0 for Q3 2020.
- In Q3 2020, Long-Term Debt Issuances changed N/A year-over-year to $62110.0; the TTM figure through Apr 2021 stood at $62110.0 (changed N/A YoY), while the FY2024 annual figure was $300000.0, changed N/A from the prior year.
- Long-Term Debt Issuances came in at $62110.0 for Q3 2020 at Alzamend Neuro.
- In the past five years, Long-Term Debt Issuances ranged from a high of $62110.0 in Q3 2020 to a low of $62110.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Alzamend Neuro | 5.54 Mn | 5.54 Mn | - | - |